Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorasidenib + ciprofloxacin
- Development stage
- Unknown
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Vorasidenib + ciprofloxacin** is a drug combination with significant pharmacokinetic interaction. Vorasidenib is an orally administered, brain-penetrant small molecule dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2), developed as a targeted therapy for grade 2 astrocytoma or oligodendroglioma with IDH1 or IDH2 mutation[1][4][5]. Ciprofloxacin is a fluoroquinolone antibacterial and acts as a moderate CYP1A2 inhibitor. When co-administered, ciprofloxacin substantially increases plasma concentrations of vorasidenib (Cmax by 1.3-fold and AUC by 2.5-fold) due to CYP1A2 inhibition, raising the risk of vorasidenib-related adverse reactions[1][3][4][5]. This combination should generally be avoided unless benefits clearly outweigh risks.
- Brand names
- Voranigo + CiproVoranigo + ciprofloxacin
- Other names
- vorasidenib + ciprofloxacin
02
Targets
IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)CYP3A (CYP3A family)IDH2 (Isocitrate dehydrogenase [NADP], mitochondrial (mutant))UGT1A4 (UDP-glucuronosyltransferase 1A4)Topo IV (Bacterial Topoisomerase IV)CYP1A2 (Cytochrome P450 1A2)DNA gyraseCYP2B6 (Cytochrome P450 2B6)CYP2C8 (Cytochrome P450 2C8)CYP2C19 (Cytochrome P450 2C19)
Beyond the preview
Go deeper on vorasidenib + ciprofloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorasidenib + ciprofloxacin.